Current Report Filing (8-k)
August 19 2016 - 5:20PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported):
August 19, 2016
ENDONOVO
THERAPEUTICS, INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
|
333-176954
|
|
45-2552528
|
|
(State
or other jurisdiction
|
|
(Commission
|
|
(IRS
Employer
|
|
of
incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
6320
Canoga Avenue, 15
th
Floor
Woodland
Hills, CA 91367
(Address
of principal executive office)(Zip Code)
Registrant’s
telephone number, including area code:
(800) 489-4774
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item
1.02 Termination of a Material Definitive Agreement.
On
August 19, 2019, we received a notice to terminate the binding letter agreement executed on July 9, 2016 (the
“Letter
Agreement”) with
Rio Grande Neurosciences, Inc. (“RGN”) previously reported on a Current Report on Form
8-K dated July 9, 2016 and filed July 11, 2016. RGN, acting through its CEO, advised us that it would not proceed with the transactions
contemplated by the Letter Agreement unless there were substantial modifications to their terms, including, but not limited to,
the payment by us of substantial monies to RGN prior to closing and the entry into a more definitive agreement; and allowing RGN
to seek other possible transactions in contravention of the non-circumvention of provisions of the Letter Agreement. We do not
believe that there will be any liability to us as a result of the termination of the Letter Agreement. RGN has confirmed that
the $500,000 note issued to RGN as an initial payment to RGN have been cancelled as a result of their notice to terminate the
Letter Agreement.
Item
9.01 Financial Statements and Exhibits.
|
(a)
|
Financial
Statements -None
|
|
(b)
|
Exhibits
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Dated:
August 19, 2016
|
|
ENDONOVO THERAPEUTICS, INC.
|
|
|
|
|
|
|
By:
|
/s/
Alan Collier
|
|
|
|
Alan
Collier
Chief
Executive Officer
|